Grifols (NASDAQ:GRFS) Shares Gap Down – What’s Next?

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $7.40, but opened at $7.00. Grifols shares last traded at $7.15, with a volume of 362,744 shares trading hands.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Down 1.6 %

The business’s 50-day moving average is $7.75 and its two-hundred day moving average is $8.21. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after buying an additional 1,181,959 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of Grifols in the 2nd quarter valued at approximately $359,000. Stifel Financial Corp acquired a new position in shares of Grifols in the 3rd quarter valued at approximately $1,043,000. GAMMA Investing LLC raised its position in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,527 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Grifols in the 3rd quarter valued at approximately $363,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.